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Background
Major obstacles for the development of immunothera-
peutics are the ability of tumors to escape the immune
system coupled with toxicity associated with systemic
administration. To overcome these challenges, we have
developed an adenoviral vector, Ad-RTS-IL-12 (AD),
administered intratumorally under control of the RheoS-
witch Therapeutic System® gene expression platform.
Expression of IL-12 mRNA and IL-12 protein is tightly
regulated by the oral administration of a small molecule
activator ligand, veledimex (AL).
Materials and methods
In preclinical studies the antitumor activity of Ad-RTS-
mIL-12 in combination with AL was studied in the mouse
B16F0 melanoma model. Melanoma (B16F0) cells were
inoculated subcutaneously into the right and left flanks of
6-8 week old female C57BL/6 mice. When tumors reached
70-100 mm3, animals received a single intratumoral (IT)
injection of Ad-RTS-mIL-12 1 x 1010 viral particles into
the right flank plus AL at a dose of ~200 mg/m2 in the
chow ad lib for the duration of the study. Tumor growth
(TG), tumor cytokines and infiltrating T cells were stu-
died. In a human Phase I, 3+3 dose escalation study,
subjects with nonresectable stage III/IV melanoma were
injected Ad-RTS-hIL-12 IT with a constant dose of 1 x
1012 viral particles on the first day of each 21-day cycle,
and escalating oral doses of AL (5, 20, 100, and 160 mg)
on Days 1-7 of each cycle. In the expanded Phase II
portion 8 subjects have been treated with 160 mg.
Results
In mice, increase in local expression of IL-12 with increas-
ing AL dose resulted in decrease in TG in both the treated
and untreated tumors coupled with an increase in tumor
infiltrating lymphocytes (TILs) as well as demonstration of
systemic immunity. In human subjects, increase in tumor
IL-12 mRNA expression and increases TILs (CD8+,
CD45RO+) were observed following treatment of Ad-RTS-
IL-12 + AL (100 or 160 mg). Clinical activity without sig-
nificant toxicity correlated with the highest serum levels of
IL-12 which induced interferon-gamma (IFN-g). Based on
these results, preclinical combination studies with signal
transduction agents and immunotherapeutics are ongoing
and will be presented.
Conclusions
Delivery of IL-12 intratumorally via an adenoviral vector
using RheoSwitch® technology enables finely-controlled
expression of IL-12, which is well tolerated and results in
an increase in TILs concomitant with a reduction in TG.
These findings form the basis for ongoing combination
studies in melanoma.
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